Skip to content

Research at St Andrews

Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients

Research output: Contribution to journalArticle

DOI

Author(s)

GLIMP investigators

School/Research organisations

Abstract

BACKGROUND: The correct management of immunocompromised patients with pneumonia is debated. We evaluated the prevalence, risk factors, and characteristics of immunocompromised patients coming from the community with pneumonia.

METHODS: We conducted a secondary analysis of an international, multicenter study enrolling adult patients coming from the community with pneumonia and hospitalized in 222 hospitals in 54 countries worldwide. Risk factors for immunocompromise included AIDS, aplastic anemia, asplenia, hematological cancer, chemotherapy, neutropenia, biological drug use, lung transplantation, chronic steroid use, and solid tumor.

RESULTS: At least 1 risk factor for immunocompromise was recorded in 18% of the 3702 patients enrolled. The prevalences of risk factors significantly differed across continents and countries, with chronic steroid use (45%), hematological cancer (25%), and chemotherapy (22%) the most common. Among immunocompromised patients, community-acquired pneumonia (CAP) pathogens were the most frequently identified, and prevalences did not differ from those in immunocompetent patients. Risk factors for immunocompromise were independently associated with neither Pseudomonas aeruginosa nor non-community-acquired bacteria. Specific risk factors were independently associated with fungal infections (odds ratio for AIDS and hematological cancer, 15.10 and 4.65, respectively; both P = .001), mycobacterial infections (AIDS; P = .006), and viral infections other than influenza (hematological cancer, 5.49; P < .001).

CONCLUSIONS: Our findings could be considered by clinicians in prescribing empiric antibiotic therapy for CAP in immunocompromised patients. Patients with AIDS and hematological cancer admitted with CAP may have higher prevalences of fungi, mycobacteria, and noninfluenza viruses.

Close

Details

Original languageEnglish
Pages (from-to)1482-1493
Number of pages12
JournalClinical Infectious Diseases
Volume68
Issue number9
DOIs
Publication statusPublished - 24 Apr 2019

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community-acquired pneumonia

    GLIMP investigators, May 2020, In : Respirology. 25, 5, p. 543-551 9 p.

    Research output: Contribution to journalArticle

  2. An international perspective on hospitalized patients with viral community-acquired pneumonia

    Radovanovic, D., Sotgiu, G., Jankovic, M., Mahesh, P. A., Marcos, P. J., Abdalla, M. I., Di Pasquale, M. F., Gramegna, A., Terraneo, S., Blasi, F., Santus, P., Aliberti, S., Reyes, L. F., Restrepo, M. I. & GLIMP Study Group, Feb 2019, In : European Journal of Internal Medicine. 60, p. 54-70 17 p.

    Research output: Contribution to journalArticle

  3. Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients

    Restrepo, M. I., Babu, B. L., Reyes, L. F., Chalmers, J. D., Soni, N. J., Sibila, O., Faverio, P., Cilloniz, C., Rodriguez-Cintron, W., Aliberti, S. & GLIMP, 9 Aug 2018, In : European Respiratory Journal. 52, 2, 1701190.

    Research output: Contribution to journalArticle

  4. Genomic investigation unmasks evidence of transmission across mycobacterium abscessus cystic fibrosis patients

    Alateah, S., Peters, C., Dhasmana, DJ., Pettigrew, K., Fallon, R., Seagar, A., Sloan, DJ., Laurenson, IF., Holden, M. & Gillespie, S., 15 Dec 2017, In : Thorax. 72, Suppl 3, p. A56-A56

    Research output: Contribution to journalAbstract

  5. Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study

    Walsh, S. L. F., Maher, T. M., Kolb, M., Poletti, V., Nusser, R., Richeldi, L., Vancheri, C., Wilsher, M. L., Antoniou, K. M., Behr, J., Bendstrup, E., Brown, K., Calandriello, L., Corte, T. J., Cottin, V., Crestani, B., Flaherty, K., Glaspole, I., Grutters, J., Inoue, Y. & 25 others, Kokosi, M., Kondoh, Y., Kouranos, V., Kreuter, M., Johannson, K., Judge, E., Ley, B., Margaritopoulos, G., Martinez, F. J., Molina-Molina, M., Morais, A., Nunes, H., Raghu, G., Ryerson, C. J., Selman, M., Spagnolo, P., Taniguchi, H., Tomassetti, S., Valeyre, D., Wijsenbeek, M., Wuyts, W., Hansell, D., Wells, A., IPF Project Consortium & Dhasmana, D. J., 31 Aug 2017, In : European Respiratory Journal. 50, 2, 10 p., 1700936.

    Research output: Contribution to journalArticle

Related by journal

  1. A sub-group of patients with hospital-acquired pneumonia do not require broad-spectrum gram-negative antimicrobial coverage

    Russell, C. D., Whittaker, E., Dee, D. P., Farquhar, E., Saenz de Villaverde, A., Evans, M. H., Laurenson, I. F., Mackintosh, C. L. & Cevik, M., 8 Apr 2020, In : Clinical Infectious Diseases. ciaa391.

    Research output: Contribution to journalArticle

  2. Late presentation with HIV in Africa: phenotypes, risk, and risk stratification in the REALITY trial

    Siika, A., McCabe, L., Bwakura-Dangarembizi, M., Kityo, C., Mallewa, J., Berkley, J., Maitland, K., Griffiths, A., Baleeta, K., Mudzingwa, S., Abach, J., Nathoo, K., Thomason, M. J., Prendergast, A. J., Walker, A. S., Gibb, D. M., Mugyenyi, P., Kityo, C., Musiime, V., Wavamunno, P. & 30 others, Nambi, E., Ocitti, P., Ndigendawani, M., Kemigisa, M., Acen, J., Olebo, D., Mpamize, G., Amone, A., Okweny, D., Mbonye, A., Nambaziira, F., Rweyora, A., Kangah, M., Kabaswahili, V., Abach, J., Abongomera, G., Omongin, J., Aciro, I., Philliam, A., Arach, B., Ocung, E., Amone, G., Miles, P., Adong, C., Tumsuiime, C., Kidega, P., Otto, B., Apio, F., Baleeta, K. & REALITY Trial Team, 1 Apr 2018, In : Clinical Infectious Diseases. 66, Issue suppl_2, p. S140-S146

    Research output: Contribution to journalArticle

  3. The potential for treatment shortening with higher rifampicin doses: relating drug exposure to treatment response in patients with pulmonary tuberculosis

    Svensson, E. M., Svensson, R. J., Te Brake, L. H. M., Boeree, M. J., Heinrich, N., Konsten, S., Churchyard, G., Dawson, R., Diacon, A. H., Kibiki, G. S., Minja, L. T., Ntingiya, N. E., Sanne, I., Gillespie, S. H., Hoelscher, M., Phillips, P. P. J., Simonsson, U. S. H. & Aarnoutse, R., 18 Jun 2018, In : Clinical Infectious Diseases. 67, 1, p. 34-41 8 p.

    Research output: Contribution to journalArticle

ID: 267634933

Top